Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YAOHAN A LAM

Allopathic & Osteopathic Physicians Dermatology

NPI
1285954305
CMS profile
827662
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$14,801.02

103 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YAOHAN A LAM

NPI 1285954305 · CMS profile ID 827662

Allopathic & Osteopathic Physicians / Dermatology

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285954305?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YAOHAN A LAM, NPI 1285954305, CMS profile ID 827662. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285954305?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). YAOHAN A LAM, NPI 1285954305, CMS profile ID 827662. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285954305?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
YAOHAN A LAM, NPI 1285954305, CMS profile ID 827662, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1285954305?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

103 matching records · $14,801.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 103 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 103.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $9.9607/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992015149 CMS
Incyte Corporation $1,100.0007/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044221673 CMS
GENZYME CORPORATION $15.1806/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050217579 CMS
Sun Pharmaceutical Industries Inc. $15.9806/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054001799 CMS
Lilly USA, LLC $16.5406/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032673093 CMS
LEO Pharma Inc. $17.9506/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053495419 CMS
Dermavant Sciences, Inc. $21.0506/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215031 CMS
Incyte Corporation $1,100.0006/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044221703 CMS
Novartis Pharmaceuticals Corporation $23.3306/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992015145 CMS
Novartis Pharmaceuticals Corporation $6.0906/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992015165 CMS
ABBVIE INC. $26.9606/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997719579 CMS
PFIZER INC. $21.7805/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050365349 CMS
Lilly USA, LLC $19.9005/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032653227 CMS
Lilly USA, LLC $24.1405/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032512105 CMS
Dermavant Sciences, Inc. $17.3505/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215027 CMS
Incyte Corporation $1,100.0005/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044221645 CMS
Novartis Pharmaceuticals Corporation $11.8805/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992015141 CMS
Regeneron Healthcare Solutions, Inc. $25.0605/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999264317 CMS
Galderma Laboratories, L.P. $15.9205/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059709951 CMS
LEO Pharma Inc. $14.1305/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053495413 CMS
E.R. Squibb & Sons, L.L.C. $24.7405/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016070347 CMS
Dermavant Sciences, Inc. $3.8905/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215023 CMS
Arcutis Biotherapeutics, Inc. $16.6004/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044888093 CMS
Incyte Corporation $2,200.0004/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044221615 CMS
LEO Pharma Inc. $19.7004/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053495409 CMS
Novartis Pharmaceuticals Corporation $13.8404/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992015137 CMS
Lilly USA, LLC $12.8904/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032672385 CMS
GENZYME CORPORATION $13.9404/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050217527 CMS
Incyte Corporation $100.3304/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044221605 CMS
Dermavant Sciences, Inc. $9.6904/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215019 CMS
Sun Pharmaceutical Industries Inc. $17.2704/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054001787 CMS
Regeneron Healthcare Solutions, Inc. $15.5104/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999264313 CMS
Sun Pharmaceutical Industries Inc. $26.3904/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054001793 CMS
Novartis Pharmaceuticals Corporation $19.2303/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992015117 CMS
Arcutis Biotherapeutics, Inc. $17.5503/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044888109 CMS
ABBVIE INC. $17.1203/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997719577 CMS
Dermavant Sciences, Inc. $6.2703/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215015 CMS
LEO Pharma Inc. $19.1003/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053495403 CMS
Novartis Pharmaceuticals Corporation $6.3002/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992015129 CMS
Arcutis Biotherapeutics, Inc. $15.7102/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044888081 CMS
Galderma Laboratories, L.P. $23.3902/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059709949 CMS
Dermavant Sciences, Inc. $14.4202/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215011 CMS
Sun Pharmaceutical Industries Inc. $13.3602/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054001781 CMS
Novartis Pharmaceuticals Corporation $5.9002/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992015125 CMS
Dermavant Sciences, Inc. $4.7102/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215007 CMS
GENZYME CORPORATION $37.3902/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050217495 CMS
Regeneron Healthcare Solutions, Inc. $26.2202/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999264309 CMS
E.R. Squibb & Sons, L.L.C. $14.4601/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016070255 CMS
Dermavant Sciences, Inc. $9.2701/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215003 CMS
Lilly USA, LLC $30.1601/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032653221 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $599.39 41
PY2020 $189.76 11
PY2021 $579.76 26
PY2022 $11,797.17 88
PY2023 $14,801.02 103
PY2024 $26,437.29 134
PY2025 $33,351.55 133

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $357,170.90 145
PY2024 Principal investigator $251,857.82 195
PY2023 Principal investigator $171,650.12 145
PY2022 Principal investigator $102,227.30 34
PY2021 Principal investigator $148,880.13 13
PY2020 Recipient $73.54 1
PY2020 Principal investigator $1,341.00 1
PY2019 Recipient $28,513.70 2
PY2019 Principal investigator $65.94 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

145 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $387.00 12/19/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536328
Principal investigator 1 Incyte Corporation $1,648.80 12/11/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536324
Principal investigator 1 Incyte Corporation $5,538.20 12/04/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536320
Principal investigator 1 Incyte Corporation $8,853.30 12/04/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536333
Principal investigator 1 Incyte Corporation $3,213.00 11/25/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536316
Principal investigator 1 Incyte Corporation $6,140.70 11/20/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536313
Principal investigator 1 Incyte Corporation $387.00 11/14/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536300
Principal investigator 1 Incyte Corporation $104.00 11/07/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536296
Principal investigator 1 Incyte Corporation $2,232.00 11/07/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536304
Principal investigator 1 Incyte Corporation $2,984.40 11/07/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536308
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 11/03/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175414734
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Central Sooner Research (Csr) - Oklahoma City
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235998212
Principal investigator 1 Incyte Corporation $2,659.50 10/29/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536287
Principal investigator 1 UCB SA $2,514.00 10/27/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246658004
Principal investigator 1 UCB SA $2,155.00 10/27/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246658006
Principal investigator 1 Incyte Corporation $885.20 10/22/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240536336
Principal investigator 1 Incyte Corporation $2,826.00 10/03/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536292
Principal investigator 1 UCB SA $700.00 09/22/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656660
Principal investigator 1 UCB SA $350.00 09/22/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656664
Principal investigator 1 UCB SA $350.00 09/22/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656667
Principal investigator 1 UCB SA $350.00 09/22/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656670
Principal investigator 1 UCB SA $350.00 09/22/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656675
Principal investigator 1 UCB SA $350.00 09/22/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656678
Principal investigator 1 Incyte Corporation $1,413.00 09/18/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536268
Principal investigator 1 Incyte Corporation $2,826.00 09/12/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536275
Principal investigator 1 UCB SA $2,155.00 08/28/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659280
Principal investigator 1 Incyte Corporation $4,608.00 08/26/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536263
Principal investigator 1 Amgen Inc. $42,000.00 08/23/2025 Non-covered Recipient Entity
HIGHTOWER CLINICAL LLC
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-nave Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1246642289
Principal investigator 1 Eli Lilly and Company $5,283.00 08/20/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH INC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187878909
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 08/01/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175414760
Principal investigator 1 Incyte Corporation $1,996.20 07/31/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536252
Principal investigator 1 UCB SA $937.00 07/23/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657894
Principal investigator 1 UCB SA $3,927.00 07/23/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657896
Principal investigator 1 UCB SA $3,011.00 07/23/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657898
Principal investigator 1 Incyte Corporation $8,577.00 07/10/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536256
Principal investigator 1 Incyte Corporation $1,500.00 07/09/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536280
Principal investigator 1 Incyte Corporation $500.00 07/09/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536284
Principal investigator 1 Incyte Corporation $1,323.00 07/04/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536260
Principal investigator 1 UCB SA $1,613.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657159
Principal investigator 1 UCB SA $1,828.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657162
Principal investigator 1 UCB SA $3,624.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657166
Principal investigator 1 UCB SA $203.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657171
Principal investigator 1 UCB SA $3,531.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657175
Principal investigator 1 UCB SA $203.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657178
Principal investigator 1 UCB SA $3,624.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657182
Principal investigator 1 UCB SA $1,167.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659605
Principal investigator 1 UCB SA $2,514.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659607
Principal investigator 1 UCB SA $2,935.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659609
Principal investigator 1 UCB SA $3,517.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659611
Principal investigator 1 UCB SA $4,102.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659613
Principal investigator 1 UCB SA $3,229.00 06/25/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659615
Principal investigator 1 UCB SA $350.00 06/20/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246658630
Principal investigator 1 UCB SA $700.00 06/20/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659589
Principal investigator 1 UCB SA $350.00 06/20/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659591
Principal investigator 1 Incyte Corporation $1,557.90 06/05/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536243
Principal investigator 1 Janssen Research & Development, LLC $2,474.00 05/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175414754
Principal investigator 1 Incyte Corporation $336.60 05/08/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536239
Principal investigator 1 UCB SA $2,155.00 04/30/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659484
Principal investigator 1 UCB SA $4,102.00 04/30/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659486
Principal investigator 1 UCB SA $203.00 04/30/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659488
Principal investigator 1 Incyte Corporation $4,288.50 04/28/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240536235
Principal investigator 1 Incyte Corporation $708.60 04/18/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240536248
Principal investigator 1 UCB SA $2,155.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656248
Principal investigator 1 UCB SA $3,531.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656252
Principal investigator 1 UCB SA $3,517.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656256
Principal investigator 1 UCB SA $203.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656260
Principal investigator 1 UCB SA $3,531.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656264
Principal investigator 1 UCB SA $3,624.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656268
Principal investigator 1 UCB SA $3,624.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656271
Principal investigator 1 UCB SA $1,828.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656276
Principal investigator 1 UCB SA $1,613.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656279
Principal investigator 1 UCB SA $1,167.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656285
Principal investigator 1 UCB SA $2,155.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246656288
Principal investigator 1 UCB SA $3,011.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659066
Principal investigator 1 UCB SA $937.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659068
Principal investigator 1 UCB SA $3,927.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659070
Principal investigator 1 UCB SA $2,514.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659072
Principal investigator 1 UCB SA $3,517.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659074
Principal investigator 1 UCB SA $3,927.00 03/26/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246659130
Principal investigator 1 Janssen Research & Development, LLC $1,459.00 03/03/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175414738
Principal investigator 1 UCB SA $3,011.00 02/10/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246657668
Principal investigator 1 UCB SA $2,155.00 02/10/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246658394
Principal investigator 1 UCB SA $113,413.00 02/10/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246658396
Principal investigator 1 UCB SA $203.00 02/10/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246658398
Principal investigator 1 UCB SA $2,935.00 02/10/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246658400
Principal investigator 1 UCB SA $3,229.00 02/10/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT, INVESTIGATOR, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1246658402
Principal investigator 1 Janssen Research & Development, LLC $6,323.00 02/07/2025 Non-covered Recipient Entity
CENTRAL SOONER RESEARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175414748
Principal investigator 1 Incyte Corporation $9.72 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536007
Principal investigator 1 Incyte Corporation $7.92 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536011
Principal investigator 1 Incyte Corporation $22.90 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536016
Principal investigator 1 Incyte Corporation $13.60 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536025
Principal investigator 1 Incyte Corporation $12.20 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536028
Principal investigator 1 Incyte Corporation $91.60 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536032
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536036
Principal investigator 1 Incyte Corporation $190.62 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536041
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536045
Principal investigator 1 Incyte Corporation $22.20 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536049
Principal investigator 1 Incyte Corporation $33.96 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536054
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536057
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536061
Principal investigator 1 Incyte Corporation $5.67 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536066
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536071
Principal investigator 1 Incyte Corporation $0.44 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536075
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536078
Principal investigator 1 Incyte Corporation $3.32 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536082
Principal investigator 1 Incyte Corporation $61.95 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536087
Principal investigator 1 Incyte Corporation $6.88 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536092
Principal investigator 1 Incyte Corporation $2.04 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536095
Principal investigator 1 Incyte Corporation $1.98 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536099
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536103
Principal investigator 1 Incyte Corporation $41.30 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536106
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536111
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536114
Principal investigator 1 Incyte Corporation $1.02 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536118
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536122
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536126
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536129
Principal investigator 1 Incyte Corporation $3.75 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536133
Principal investigator 1 Incyte Corporation $29.39 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536137
Principal investigator 1 Incyte Corporation $3.78 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536141
Principal investigator 1 Incyte Corporation $104.56 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536145
Principal investigator 1 Incyte Corporation $2.50 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536149
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536154
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536158
Principal investigator 1 Incyte Corporation $0.56 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536162
Principal investigator 1 Incyte Corporation $16.18 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536166
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536171
Principal investigator 1 Incyte Corporation $76.92 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536175
Principal investigator 1 Incyte Corporation $29.39 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536179
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536183
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536186
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536191
Principal investigator 1 Incyte Corporation $5.55 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536196
Principal investigator 1 Incyte Corporation $24.36 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536200
Principal investigator 1 Incyte Corporation $0.84 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536203
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536208
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536213
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536218
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536222
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536226
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536228
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240536231
Principal investigator 1 Incyte Corporation $40.32 01/02/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240535999
Principal investigator 1 Incyte Corporation $148.68 01/02/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240536003
Principal investigator 1 Incyte Corporation $3.93 01/02/2025 Non-covered Recipient Entity
FORCARE CLINICAL RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240536020